Luteinizing hormone (LH) acts on the granulosa cells that surround the oocyte in mammalian preovulatory follicles to cause meiotic resumption and ovulation. Both of these responses are mediated primarily by an increase in cAMP in the granulosa cells, and activity of the cAMP phosphodiesterase PDE4 contributes to preventing premature responses. However, 2 other cAMP-specific phosphodiesterases, PDE7 and PDE8, are also expressed at high levels in the granulosa cells, raising the question of whether these phosphodiesterases also contribute to preventing uncontrolled activation of meiotic resumption and ovulation. Using selective inhibitors, we show that inhibition of PDE7 or PDE8 alone has no effect on the cAMP content of follicles, and inhibition of PDE4 alone has only a small and variable effect. In contrast, a mixture of the 3 inhibitors elevates cAMP to a level comparable to that seen with LH. Correspondingly, inhibition of PDE7 or PDE8 alone has no effect on meiotic resumption or ovulation, and inhibition of PDE4 alone has only a partial and slow effect. However, the fraction of oocytes resuming meiosis and undergoing ovulation is increased when PDE4, PDE7, and PDE8 are simultaneously inhibited. PDE4, PDE7, and PDE8 also function together to suppress the premature synthesis of progesterone and progesterone receptors, which are required for ovulation. Our results indicate that 3 cAMP phosphodiesterases act in concert to suppress premature responses in preovulatory follicles.
Introduction
In cells in which physiological responses are elicited by hormones that elevate cAMP, it is critical that cAMP stays low prior to hormonal stimulation. To ensure that cAMP-dependent processes do not occur prematurely, cAMP phosphodiesterases are continuously active in many tissues (see Discussion), including granulosa cells of the ovarian follicle (1) (2) (3) . The mammalian ovarian follicle is a spherical complex of thousands of granulosa cells surrounding an oocyte in the center. The oocyte's meiotic cell cycle is paused at prophase, and cyclic nucleotide levels must be precisely controlled to maintain the arrest until with each reproductive cycle, a subset of follicles respond to luteinizing hormone (LH) (4-6). LH acts on its receptors in the granulosa cells to activate the G-protein G s , thus activating adenylyl cyclase and elevating cAMP, and the cAMP rise in the granulosa cells is a primary stimulus for reinitiation of meiosis in the oocyte and for ovulation (5, 6). LH signaling triggers other responses as well, including activation of the GLYT1 glycine transporter in the oocyte, allowing cell volume regulation (7) and the activation of genes leading to granulosa cell luteinization (8) preovulatory increase in LH, during which serum levels of LH stay elevated for a period of several hours (9). Although the LH receptor activates other G-proteins in addition to G s (5), prevention of untimely cAMP elevation is essential for preventing premature responses in the follicle.
Previous studies have indicated that activity of the cAMP phosphodiesterase PDE4 contributes to preventing meiosis and ovulation from occuring prematurely. PDE4 inhibitors promote resumption of meiosis in isolated follicles (2, 3) , and injection of some (but not other) PDE4 inhibitors into rats causes progesterone production and ovulation (10). However, PDE4 accounts for only 20-30% of the total cAMP phosphodiesterase activity in mouse preovulatory ovaries (11, 12) , and for only 15-20% of the cAMP phosphodiesterase activity in bovine and rat mural granulosa cells (13, 14) .
In preovulatory mural granulosa cells of mice, rats, and humans, levels of mRNA encoding the cAMP-specific phosphodiesterases PDE7A, PDE7B, PDE8A, and PDE8B are much higher than those encoding the 4 isoforms of PDE4 (14-16). Furthermore, PDE8 accounts for ~40% of the cAMP phosphodiesterase activity in bovine and porcine mural granulosa cells (13, 17) . Studies of a T-cell line have indicated that inhibition of PDE7 and PDE8 results in phosphorylation of a set of proteins distinct from those that are phosphorylated when PDE4 is inhibited (18). These findings, as well as extensive evidence that PDE4, PDE7, and PDE8 often act together in other cells to control cAMP-dependent processes (see Discussion), led us to investigate the function of these 3 phosphodiesterases in mouse ovarian follicles. Here we use a new PDE7 inhibitor, alone or in combination with PDE4 and PDE8 inhibitors, to test the effects of inhibiting these phosphodiesterases on cAMP levels, meiotic resumption, ovulation, and production of progesterone and its receptors.
Materials and Methods

Phosphodiesterase inhibitors
The PDE4 inhibitor rolipram was obtained from Tocris BioScience (Bristol, UK). The PDE7 and PDE8 inhibitors, referred to here as PDE7i and PDE8i (also called PF-04957325), were obtained from Pfizer Worldwide Research and Development (Groton, CT). The chemical structure of the PDE7 inhibitor is shown in Fig. S1 . For comparison, this figure also shows the previously published structures of rolipram (19) and PF-04957325 (20). PF-04957325 is now available from MedChemExpress (Monmouth Junction, NJ). Stock solutions were made in DMSO and stored at -80 o C. Final DMSO concentrations after dilution were as follows: 1 µM PDE7i, 0.003% DMSO; 1 µM PDE8i, 0.002% DMSO; 5 µM rolipram, 0.005% DMSO; 20 µM rolipram, 0.02% DMSO; 5 µM rolipram + 1 µM PDE7i + 1 µM , 0.01% DMSO. By itself, 0.1% DMSO did not cause meiotic resumption or ovulation in cultured ovarian follicles, and did not affect the time course of meiotic resumption in response to LH (Fig. S2) . Since the highest concentration of DMSO that was used in the solutions of phosphodiesterase inhibitors was less than this (0.02%), DMSO was not included in controls without phosphodiesterase inhibitors.
Rolipram has an IC 50 for PDE4 of 70-140 nM, measured with 1 µM cAMP substrate, while IC 50 values for all other cyclic nucleotide phosphodiesterases are >100 µM (21-24). The PDE7 and PDE8 inhibitors are also highly selective. K i values for the PDE7 and PDE8 inhibitors were determined as previously described (25), for a member of each cyclic nucleotide phosphodiesterase family. These data, shown in Table 1 , were supplied by Steve Jenkinson (Pfizer). In brief, PDE activity was measured using a scintillation proximity assay (SPA) that measures the inhibition by the indicated compounds of the activity of the human recombinant phosphodiesterases listed in Table 1 (except for PDE6 , which was extracted from bovine retina) as determined in vitro using lysates or FLAG-tag purified enzymes. The assays were performed in a 384-well format. These assays were used to measure the hydrolysis of Table  1 . The enzyme stocks were thawed slowly and diluted in assay buffer containing 50 mM Tris HCl buffer (pH 7.5 at room temperature) and 1.3 mM MgCl 2 . Additionally, the PDE1 assay buffers contained 2.8 mM CaCl 2 , and the activator calmodulin at a final assay concentration of 100 units/ml. The enzyme concentration for each isoform was determined by enzyme titration experiments to achieve 20-30% substrate turn-over at 30 minutes, with the exception of the PDE6 reactions, which were incubated for 60 minutes. The final substrate concentration used was at sub-K m levels (20 nM for [ 3 H]cAMP and 50 nM for [ 3 H]cGMP) so that IC 50 values would approximate the K i values. In all cases, these reactions were well within the linear portion of the assay.
The reaction was stopped by the addition of phosphodiesterase SPA beads (Perkin Elmer) at a final assay concentration of 0.2 mg/well. The PDE9 assay required the extra addition of a potent PDE9 inhibitor, PF-00509783, at a high concentration (10 µM) prior to adding beads in order to completely stop the reaction. The products, [ 3 H]GMP and [ 3 H]AMP, bound preferentially to yttrium silicate SPA beads and were detected by scintillation counting in a Microbeta Trilux Counter (PerkinElmer). The inhibition of enzyme activity was calculated relative to the activity of uninhibited controls (DMSO) and fully inhibited (high concentration of known inhibitor). To determine IC 50 values, the compounds were tested in duplicate using a half-log dilution scheme with the top concentration of 10 µM. The corresponding IC 50 values of the compounds for the inhibition of PDE activities were determined from the concentrationeffect curves by using a four-parameter logistic fit. Apparent K i values were estimated by using the Cheng-Prusoff equation: -K i = (IC 50 )/(1 + [S]/K m ), where S is the substrate, and K m is the substrate concentration at which half the enzyme's active sites are occupied by substrate.
The mean K i for PDE7i inhibition of PDE7B is 7.8 nM, compared with ≥3.8 µM for all other cyclic nucleotide phosphodiesterase families ( Table 1) . The K i for PDE7i inhibition of PDE7A was not determined. The mean K i for PDE8i inhibition of PDE8B is 0.1 nM, compared with ≥2.5 µM for all other cyclic nucleotide phosphodiesterase families (Table 1) . These measurements are close to previously published IC 50 values for this inhibitor (20, 26, 27) . These previous studies reported IC 50 values for this inhibitor that are ~2-8 times higher for PDE8A than for PDE8B, but still much lower than for all other cyclic nucleotide phosphodiesterase families (see Table 1 legend).
Mice and follicle culture
Prepubertal B6SJLF1 mice (23-25 days old) from The Jackson Laboratory (Bar Harbor, ME) were used for all experiments. Procedures were approved by the animal care committee of the University of Connecticut Health Center.
Ovarian follicles, 320-400 µm in diameter, were isolated using fine forceps. Before use, the follicles were cultured for 24-30 hours on Millicell organotypic membranes (Merck Millipore Ltd, Cork, IRL; PICMORG50) (28, 29). 3 mg/ml BSA was included in the culture medium in place of serum. 1 nM (30 ng/ml) of follicle stimulating hormone (FSH) was included in the medium to stimulate follicle growth and expression of LH receptors. The use of FSH at 1 nM instead of 0.3 nM (10 ng/ml) that we have used previously was an improvement; with 1 nM Observations of follicles on Millicell membranes were made using an upright microscope with a 20x/0.4 NA long-working distance objective. LH or phosphodiesterase inhibitors were applied to the medium in the dish holding the Millicell membrane, and oocytes within follicles were observed for the presence or absence of a nuclear envelope and nucleolus at 1-hour intervals. Photographs of follicles were taken on the Millicell membranes. Ovulation was scored at 24 hours.
cAMP measurement
Follicles were sonicated in 0.1 M HCl, and cAMP was measured with a direct cAMP ELISA kit from Enzo (Farmingdale, NY) (ADI-900-066). This kit is highly selective for cAMP, and shows only 0.33% cross reactivity with AMP, 0.12% with ATP, and <0.001% with cGMP, GMP, GTP, cUMP, and CTP (manufacturer's product information sheet). Inter-assay precision was determined by comparing the standard curves obtained in 16 separate assays, using cAMP solutions prepared from a stock solution provided with the kit. The coefficient of variation (standard deviation/mean x 100) at the mid-point concentration was 14.5%. Intra-assay precision was determined by assaying 14 replicates of the midpoint concentration in a single assay; the coefficient of variation was 1.2%.
Progesterone measurement
Progesterone in the culture media was measured using an ELISA kit from Cayman Chemical Company (Ann Arbor, MI) (582601). This kit is selective for progesterone, but shows a small amount of cross-reactivity with prenenolone (14%), 17β-estradiol (7.2%), 5β-pregnan-3α-ol-20-one (6.7%), and 17α-hydroxyprogesterone (3.6%) (manufacturer's product information sheet). Inter-assay precision was determined by comparing the standard curves obtained in 16 separate assays, using progesterone solutions prepared from a stock solution provided with the kit. The coefficient of variation at the mid-point concentration was 24.3%. Intra-assay precision was determined by assaying 7 replicates of the midpoint concentration in a single assay; the coefficient of variation was 6.2%.
Western blotting
Samples for western blotting were prepared by sonicating follicles in Laemmli sample buffer containing 75 mM DTT, 10 mM NaF, 1 mM Na 3 VO 4 , 1 mM Pefabloc (Sigma-Aldrich, St. Louis, MO), and Complete Mini EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The progesterone receptor (PGR) antibody was obtained from Abcam (ab 16661, rabbit monoclonal, clone SP2; Table 2 ). This antibody recognizes both PGR-A and PGR-B isoforms (32). The tissue culture supernatant was used at a dilution of 1:500. The PGR antibody was detected using a fluorescent secondary antibody (IRDye800 CW, 926-32211 from LICOR BioSciences, Lincoln, NE). Binding of the secondary antibody was quantified using the LICOR BioSciences Odessey infrared imaging system. Variability in the amount of total protein loaded in each lane was <5% as confirmed by densitometry of staining with Swift Membrane Stain (GBiosciences, St. Louis, MO). Methods were the same as previously described (16), except that 3 H-cAMP was used instead of 3 H-cGMP.
Statistics
Data were analyzed by one-way ANOVA or unpaired t-test followed by the Holm-Sidak correction for multiple comparisons, as appropriate, using Prism software (GraphPad, La Jolla, CA). Percent data were transformed by arc sine square root transformation prior to analysis. All values indicate mean ± s.e.m. Numbers in parentheses indicate the numbers of independent experiments, and asterisks and different letters indicate significant differences (p<0.05). Each experiment included 8-16 follicles.
Results
PDE4, PDE7, and PDE8 act together to suppress premature cAMP elevation in preovulatory follicles
The LH receptor stimulates cAMP formation by activating the G protein G s in granulosa cells, and the resulting elevation of cAMP is a major component of the signal that causes meiotic resumption from prophase arrest (5, 6). As background for investigating the role of phosphodiesterases in suppressing premature cAMP elevation, we first characterized the LHinduced cAMP increase under our experimental conditions, by measuring the cAMP content of mouse preovulatory follicles at various times after application of various concentrations of LH (Fig. 1A) . Concentrations of LH that were sufficient to maximally stimulate meiotic resumption in our culture system (≥10 nM) (see Fig. 2B below) increased the cAMP content by ~5-fold at 30 minutes. The cAMP content then declined gradually, but was still above baseline at 4 hours (Fig.  1A ). These cAMP levels are similar to those determined in a previous study in which the LH receptor of mouse ovarian follicles was stimulated with human chorionic gonadotropin (33).
A smaller and slower elevation of cAMP occurred with 1 nM LH (Fig. 1A ), corresponding to a slower resumption of meiosis ( Fig. 2B ). At 0.5 to 3 hours after 1 nM LH addition, cAMP content of the follicles was not statistically different from that of follicles that were incubated without LH (Fig. 1A) . However, measurements at 4 hours after addition of 1 nM LH showed a significant increase in cAMP (Fig. 1A) . 1 nM is similar to the peak serum concentration of LH during the preovulatory surge in mice (9, 34), although the concentration dependence of meiotic resumption in response to purified ovine LH applied to follicles in vitro may not be identical to that when the native hormone is delivered to follicles in vivo.
To investigate which cAMP phosphodiesterases contribute to suppressing premature elevation of cAMP prior to LH exposure, we measured the cAMP content of follicles after exposure to selective inhibitors of PDE4 (rolipram, 5 µM), PDE7 (1 µM), or PDE8 (1 µM), alone or in combination. The inhibitor concentrations were chosen based on the in vitro selectivity data described in Table 1 . Because inhibitor concentrations in the cytoplasm may be lower than those in the medium, due to limited permeability of the plasma membrane, we used the highest concentrations at which the inhibitors showed selectivity among different phosphodiesterases. At 5 µM, rolipram inhibition of PDE7 and PDE8 is insignificant, since the IC 50 for PDE7 and PDE8 is >100 µM (21-24). At 1 µM, there could be minor inhibition by the PDE7 inhibitor of PDE4 and PDE8, and minor inhibition by the PDE8 inhibitor of PDE4 and PDE7, based on measurements of the effects of these inhibitors on activity of recombinant proteins in vitro (Table 1 ). Higher concentrations of the PDE7 and PDE8 inhibitors were not tested because of the possibility of cross-reactivity with other phosphodiesterases, and these inhibitors were used at 1 µM for all subsequent experiments. Measurements made at 30 or 60 minutes after application of a mixture of the 3 inhibitors showed little or no increase in cAMP content (Fig. 1A) , consistent with the relatively slow action of these inhibitors on biological responses as described below. However, when measurements were made at 2 or 4 hours, the 3 inhibitors together increased the cAMP content by 2-4 fold (Fig.  1A,B) .
A 4-hour treatment with rolipram alone caused a small increase in cAMP content in 2 of 3 experiments, but the mean value for the 3 experiments was not statistically different from the cAMP content with no treatment. A 4-hour treatment with either the PDE7 inhibitor or the PDE8 inhibitor had no detectable effect (Fig. 1B) . A large increase in cAMP content was seen, however, in response to a 4-hour treatment with a mixture of the 3 inhibitors (Fig. 1B) , indicating that these 3 phosphodiesterases act together to maintain cAMP at a low level prior to LH exposure. This synergistic action of the 3 cAMP inhibitors when applied together was also seen in various biological responses as described below.
PDE4, PDE7, and PDE8 act together to suppress premature meiotic resumption in follicle-enclosed oocytes
To monitor the time course of meiotic resumption, follicles were cultured on the surface of Millicell membranes such that they were slightly flattened, allowing observation of the oocyte and its nucleus within the intact follicle ( Fig. 2A) (28). The first obvious sign of meiotic resumption is the breakdown of the nuclear envelope (NEBD), marking the transition from prophase to metaphase. Under the culture conditions used here, 100% of oocytes underwent NEBD by 6 hours after exposure to 10 or 300 nM LH (Fig. 2B ). 1 nM LH also caused NEBD in some follicles, but the response was delayed (Fig. 2B) , consistent with the lower amplitude and slower time course of cAMP elevation in response to LH (Fig. 1A) .
Using this culture system, we investigated the effect of inhibitors of PDE4, PDE7, and PDE8 on maintenance of meiotic arrest. At 6 hours, ~15% of the follicles treated with 5 µM of the PDE4 inhibitor rolipram had undergone NEBD (Fig. 2C) . A higher concentration of rolipram, 20 µM, did not increase the fraction of oocytes resuming meiosis (Fig. 2D) , consistent with a previous report (2) . Therefore, we used 5 µM rolipram for all subsequent experiments, except as noted.
None of the follicles treated with 1 µM of the PDE7 or PDE8 inhibitors had undergone NEBD at 6 hours (Fig. 2C) . However, when follicles were treated with a mixture of 5 µM rolipram and 1 µM each of the PDE7 and PDE8 inhibitors, ~60% of the follicles had undergone NEBD at 6 hours (Fig. 2C) . These results indicate that PDE4, PDE7, and PDE8 act together to suppress spontaneous NEBD. Mixtures of the PDE4 and PDE7 inhibitors, or of the PDE4 and PDE8 inhibitors, also showed a synergistic stimulation of NEBD (Fig. 2C) . Based on their effects on recombinant proteins in vitro (Table 1 ), 1 µM of the PDE8 or PDE7 inhibitors could cause a slight inhibition of PDE4, if this concentration was reached in the cytoplasm. However, this is unlikely to account for the synergistic effect of combining 1 µM of the PDE7 or PDE8 inhibitors with 5 µM rolipram, since no increase in nuclear envelope breakdown was seen with 20 µM vs 5 µM rolipram (Fig. 2D) .
The time course of NEBD in response to the mixture of PDE inhibitors showed an approximately 2 hour delay compared with the response to a saturating level of LH (300 nM) (Fig. 2E) . Correspondingly, the cAMP content of follicles was not significantly elevated from baseline until 2 hours after applying the mixture of PDE inhibitors (Fig. 1A) . Co-incubation with 0.1 nM or 1 nM LH did not increase the rate of NEBD in response to the mixture of cAMP phosphodiesterase inhibitors (Fig. S3 ).
ADVANCE ARTICLE: Endocrinology
When follicles were observed at 24 hours after treatment with rolipram alone, ~70% had undergone NEBD (Fig. 2E) . This finding is consistent with previous studies in which follicles were exposed to rolipram for 24 hours (2, 3; David Calebiro, personal communication about the timing of the experiments reported in reference 3). Even at 24 hours, no NEBD was seen in follicles treated with 1 µM of the PDE7 or PDE8 inhibitors alone or in combination (Fig. 2E) . However, when these inhibitors were combined with rolipram, the percentage of NEBD at 24 hours increased to 100% vs ~70% with rolipram alone (Fig. 2E) .
PDE4, PDE7, and PDE8 act together to suppress premature ovulation LH causes ovulation at least in part by signaling through G s to elevate cAMP (5, 33), although signaling through G q/11 to elevate IP 3 also contributes (5, 35). At 24 hours after applying LH to isolated follicles in culture, the oocyte has been released, and often a polar body can be seen (Fig. 3A) . Some of the granulosa cells are also released. Approximately 80% of follicles treated with 1-300 nM LH ovulated (Fig. 3B) . To investigate which cAMP phosphodiesterases contribute to suppressing premature ovulation, we investigated the effects of cAMP PDE inhibitors on this process.
Inhibition of PDE4 alone, using 5 or 20 µM rolipram, caused ovulation in ~20% of follicles (Fig. 3C,D) . The PDE7 and PDE8 inhibitors, used at 1 µM, alone or in combination, did not cause ovulation (Fig. 3C) . However, when the PDE7 or PDE8 inhibitor, or both, were applied together with rolipram, ~80% of follicles ovulated, as seen with LH (Fig. 3C,E) . Thus, as with the stimulation of cAMP elevation and meiotic resumption, PDE4, PDE7, and PDE8 act together to suppress premature ovulation.
PDE4, PDE7, and PDE8 all contribute to suppressing premature production of progesterone and progesterone receptors
An aspect of the LH-induced signaling network that is essential for ovulation, although not for meiotic progression, is the synthesis by the granulosa cells of progesterone and its receptors PGR-A and PGR-B (36-40). Synthesis of progesterone and its receptors started between 1-2 hours after exposure to LH (300 nM) (Fig. 4A,B) , consistent with previous studies (32, 38, 41-44).
To determine whether premature progesterone production by the follicle is suppressed by constitutive cAMP phosphodiesterase activity, we measured progesterone released into the medium at 6 hours after application of PDE inhibitors. As for the previous analyses, rolipram was used at a concentration of 5 µM, and PDE7 and PDE8 inhibitors were both used at 1 µM. Application of rolipram alone resulted in a progesterone level ~50% of that seen with LH (Fig.  4C) . Application of either the PDE7 or the PDE8 inhibitor alone each resulted in a progesterone level ~20% of that seen with LH (Fig. 4C) . A mixture of the 3 inhibitors resulted in a progesterone level that was the same as that seen with LH (Fig. 4C) . The effect of the 3 inhibitors on progesterone production was additive, but not synergistic.
To investigate if inhibition of PDE4, PDE7, or PDE8 results in synthesis of progesterone receptors, follicles were treated with inhibitors of each of these phosphodiesterases, alone or in combination (Fig. 4D-F) . Treatment for 6 hours with rolipram resulted in a level of PGR protein that was ~40% of that seen with LH, while neither the PDE7 nor the PDE8 inhibitor resulted in detectable PGR protein expression. However, treatment with a mixture of the 3 inhibitors reproduced the rise in PGR protein seen with LH, indicating that these cAMP phosphodiesterases act together to suppress progesterone receptor synthesis. Although LH signaling elevates cAMP by stimulating G s and increasing the activity of adenylyl cyclase (5), this signaling could be amplified by an LH-induced decrease in cAMP phosphodiesterase activity. To investigate this possibility, we measured cAMP phosphodiesterase activity in lysates of follicles that had been treated with or without LH (300 nM). Because the peak cAMP increase after LH exposure occurs at 30 minutes (Fig. 1A) , samples were prepared at this time point. Activity was assayed with 2 different cAMP substrate concentrations, 0.1 µM or 1 µM. No difference in activity was seen as a result of the LH treatment, indicating that at least on the time scale investigated, LH signaling does not decrease cAMP phosphodiesterase activity as detected in cell lysates (Fig. 5) . By 2 hours after LH receptor stimulation, the amounts of PDE4D protein and PDE4 activity actually increase (12). These results support the conclusion that although cAMP phosphodiesterases contribute to suppressing spontaneous nuclear envelope breakdown and ovulation prior to the preovulatory increase in LH, the initial rise in cAMP after LH exposure is not amplified by a decrease in cAMP phosphodiesterase activity.
Discussion
Our findings indicate that 3 families of cAMP phosphodiesterases -PDE4, PDE7, and PDE8 -act together in mouse ovarian follicles to suppress premature cAMP elevation, meiotic resumption and ovulation prior to the preovulatory increase in luteinizing hormone. The observation that exposure to PDE7 and PDE8 inhibitors has no effect in the absence of PDE4 inhibition indicates that the amount of PDE4 is sufficient to prevent premature resumption of meiosis under these experimental conditions. PDE4 inhibition alone, however, produces a submaximal response that is potentiated by concurrent inhibition of PDE7 and PDE8. These observations indicate a 'redundancy' of phosphodiesterases regulating meiotic arrest and ovulation, with PDE4 by itself being sufficient, but with PDE7 and PDE8 serving as 'back-up' regulators. However, this description of the roles of PDE7 and PDE8 as 'back-up' regulators applies only to the specific biological responses that we investigated. cAMP is a pleiotropic second messenger, and there may be unique roles for PDE7 and PDE8, vs PDE4, in particular cAMPmediated pathways in ovarian follicles. Consistent with this concept, our observations at 24 hours after inhibition of PDE4 activity indicate a more pronounced effect on ovulation than on NEBD.
Studies of other cells also indicate differential effects of inhibition of PDE4, PDE7, and PDE8. Phosphoproteomic analysis of a T-cell line has shown that PDE4 inhibition (when combined with PDE3 inhibition) results in phosphorylation of a set of proteins that is distinct from the set of proteins that are phosphorylated as a result of inhibition of PDE7 and PDE8 (when combined with PDE1 inhibition) (18). Correspondingly, the biological processes regulated by these different phosphodiesterase inhibitor combinations differ (18). Likewise, individual phosphodiesterases have been demonstrated to have distinct functional roles in cardiac myocytes, where raising intracellular cAMP content through PDE2 inhibition has anti-hypertrophic effects in neonatal rat ventricular myocytes, while inhibition of PDE3 generates pro-hypertrophic signals (45). Correspondingly, the subcellular localization of PDE2 differs from that of PDE3 (45). Spatially distinct cAMP phosphodiesterase signaling domains may be present in ovarian follicles as well, where they may contribute to the divergent signaling pathways that control different responses to LH. Cooperative function of cAMP-hydrolyzing phosphodiesterases has also been found in Leydig cells of the testis, which produce testosterone in response to luteinizing hormone (LH). Inhibition of either of 2 different cAMP-specific phosphodiesterases, PDE4 and PDE8, can induce steroid production in these cells, and inhibition of both of these enzymes increases steroid production more than the sum of either alone (26, 46). However, while PDE4 has the primary role and PDE8 a supporting role in regulating meiotic arrest in granulosa cells, the situation is reversed is in Leydig cells, with PDE8 having the primary role and PDE4 a supporting role.
Multiple cAMP phosphodiesterases act together to suppress cAMP-dependent responses in other cells as well. These include cells of the adrenal cortex (47, 48), smooth muscle (49, 50), adipose tissue (51) and leukocytic cell lines (52, 53). Having more than one type of PDE protein present to suppress premature cAMP elevation could help to ensure that conditions that might reduce the activity of any individual phosphodiesterase would not disrupt essential cellular processes. Other factors, such as cAMP buffering by high concentrations of the regulatory subunits of protein kinase A, may also contribute to preventing premature cAMP-dependent responses (54). Identification of cAMP-dependent protein kinase holoenzymes in preantral-and preovulatoryfollicle-enriched ovaries, and their association with A-kinase-anchoring proteins. Biochem J 1999; 344 Pt 2:613-623 Figure 1 . PDE4, PDE7, and PDE8 act together to suppress premature cAMP elevation in preovulatory follicles. A) Time course of cAMP elevation after exposure of follicles to various concentrations of LH, or to a mixture of inhibitors of 3 cAMP phosphodiesterases: PDE4i (rolipram, 5 µM), PDE7i (1 µM), and PDE8i (PF04957325, 1 µM). The LH data were obtained from the indicated number of independent experiments, each including all time points. The PDE inhibitor data includes 2-4 measurements for each time point. T-tests were performed to test the statistical significance of the difference between the measurements following no LH and 1 nM LH treatments; the black asterisk indicates a significant difference (p<0.05 after correction for multiple comparisons). T-tests were also used to test the difference between measurements following no LH and PDE inhibitor treatments; green asterisks indicate significant differences. B) cAMP content of follicles after a 4-hour exposure to each of the inhibitors listed in A, or to a mixture of the 3 inhibitors. Here and in subsequent figures, different letters indicate significant differences (p<0.05). Table 1 . Selectivity data for the PDE7 and PDE8 inhibitors. Assays were performed using recombinant human phosphodiesterase proteins, except for PDE6, which was extracted from bovine retina. Table 1A lists mean values for the dissociation constant of the enzyme-inhibitor complex (K i ) for the PDE7 inhibitor (PDE7i) and for the PDE8 inhibitor (PDE8i), determined for the indicated phosphodiesterases and substrates. Tables 1B and 1C list mean ± s.e.m. values for pKi (the negative of the base 10 logarithm of the Ki), testing PDE7i (Table 1B) and PDE8i (Table 1C) with the indicated phosphodiesterases. N indicates the number of assays. Mean IC 50 values for PDE8i inhibition of PDE8A and PDE8B were previously reported to be 0.7 and <0.3 nM respectively (20; substrate concentration not specified) and 3.1 and 0.4 nM respectively (27; 12-14 nM cAMP substrate). 
